According to a research report published on Tuesday, pfizer's breast cancer drug Ibrance (also known as palbociclib) has shown encouraging effects in treating a certain type of appendiceal cancer.

Studies have shown that Ibrance can stabilize tumor growth in patients with peritoneal mucinous carcinomatosis and reduce levels of blood tumor markers. This type of cancer is rare and typically resistant to standard chemotherapy.

This study also indicates that Ibrance can slow down or stop the proliferation of cancer cells. Researchers added that the next step is to test this drug with chemotherapy and targeted therapy to see if its effectiveness can be enhanced.